Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kevin Winthrop

Showing results (51-60 of 80) with videos related to

Pageof 8
Sort By:
Arthritis Care & Research|February 12, 2019
Timing of Abatacept Before Elective Arthroplasty and Risk of Postoperative OutcomesMichael D George, Joshua F Baker, Kevin Winthrop, et al.
Annals of Internal Medicine|May 21, 2019
Risk of Biologics and Glucocorticoids in Patients With Rheumatoid Arthritis Undergoing Arthroplasty: A Cohort StudyMichael D George, Joshua F Baker, Kevin Winthrop, et al.
RMD Open|February 27, 2020
Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritisMasayoshi Harigai, Kevin Winthrop, Tsutomu Takeuchi, et al.
Mbio|May 21, 2024
Immunological and microbial shifts in the aging rhesus macaque lung during nontuberculous mycobacterial infectionIsaac R Cinco, Ethan G Napier, Nicholas S Rhoades, et al.
Emerging Infectious Diseases|June 5, 2003
Leptospirosis in "Eco-Challenge" athletes, Malaysian Borneo, 2000James Sejvar, Elizabeth Bancroft, Kevin Winthrop, et al.
Rheumatology and Therapy|December 31, 2021
Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 TrialsGerd R Burmester, Kevin Winthrop, Ricardo Blanco, et al.
Research Square|February 13, 2026
Lung microbial dysregulation and TNF inhibition contribute to worsened nontuberculous mycobacterial lung diseaseEthan Napier, Isaac Cinco, Ethan Stuart, et al.
American Journal of Clinical Dermatology|June 18, 2024
Integrated Safety Update of Abrocitinib in 3802 Patients with Moderate-to-Severe Atopic Dermatitis: Data from More than 5200 Patient-Years with Up to 4 Years of ExposureEric L Simpson, Jonathan I Silverberg, Audrey Nosbaum, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 12, 2022
A Randomized, Placebo-Controlled Phase III Extension Trial of the Long-Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus ErythematosusKenneth C Kalunian, Richard Furie, Eric F Morand, et al.
Annals of the Rheumatic Diseases|February 11, 2025
Efficacy of Janus kinase inhibitors in immune-mediated inflammatory diseases a systematic literature review informing the 2024 update of an international consensus statementVictoria Konzett, Josef S Smolen, Peter Nash, et al.
Pageof 8

Showing results (51-60 of 80) with videos related to

Sort By:
Pageof 8
Arthritis Care & Research|February 12, 2019
Timing of Abatacept Before Elective Arthroplasty and Risk of Postoperative OutcomesMichael D George, Joshua F Baker, Kevin Winthrop, et al.
Annals of Internal Medicine|May 21, 2019
Risk of Biologics and Glucocorticoids in Patients With Rheumatoid Arthritis Undergoing Arthroplasty: A Cohort StudyMichael D George, Joshua F Baker, Kevin Winthrop, et al.
RMD Open|February 27, 2020
Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritisMasayoshi Harigai, Kevin Winthrop, Tsutomu Takeuchi, et al.
Mbio|May 21, 2024
Immunological and microbial shifts in the aging rhesus macaque lung during nontuberculous mycobacterial infectionIsaac R Cinco, Ethan G Napier, Nicholas S Rhoades, et al.
Emerging Infectious Diseases|June 5, 2003
Leptospirosis in "Eco-Challenge" athletes, Malaysian Borneo, 2000James Sejvar, Elizabeth Bancroft, Kevin Winthrop, et al.
Rheumatology and Therapy|December 31, 2021
Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 TrialsGerd R Burmester, Kevin Winthrop, Ricardo Blanco, et al.
Research Square|February 13, 2026
Lung microbial dysregulation and TNF inhibition contribute to worsened nontuberculous mycobacterial lung diseaseEthan Napier, Isaac Cinco, Ethan Stuart, et al.
American Journal of Clinical Dermatology|June 18, 2024
Integrated Safety Update of Abrocitinib in 3802 Patients with Moderate-to-Severe Atopic Dermatitis: Data from More than 5200 Patient-Years with Up to 4 Years of ExposureEric L Simpson, Jonathan I Silverberg, Audrey Nosbaum, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 12, 2022
A Randomized, Placebo-Controlled Phase III Extension Trial of the Long-Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus ErythematosusKenneth C Kalunian, Richard Furie, Eric F Morand, et al.
Annals of the Rheumatic Diseases|February 11, 2025
Efficacy of Janus kinase inhibitors in immune-mediated inflammatory diseases a systematic literature review informing the 2024 update of an international consensus statementVictoria Konzett, Josef S Smolen, Peter Nash, et al.
Pageof 8